Oncology
Developing precision gene therapies and immunotherapies to target cellular aberrations, overcome tumour immune evasion, and neutralize tumor progression.
Biological Focus & Mechanisms
Immune Evasion Disruption
Neutralizing tumour-derived immunosuppressive cytokines (TGF-beta, IL-10) in the microenvironment.
Targeted Vector Tropism
Restricting therapeutic transgene expression strictly to malignant cells via dual-promoter logic.
Synthetic Biology Circuits
Designing intracellular sensor-actuator switches responsive only to aberrant oncogenic drivers.
Combination Synergies
Co-administering with standard-of-care checkpoint inhibitors and targeted therapies to prevent resistance.
Development Pipeline & Logic
Genomic Target Profiling
Identifying clonal driver mutations in patient-derived tumour organoid libraries.
Circuit Construction
Synthesizing and benchmarking selective tumour-suppressive gene payloads in vitro.
Immune Infiltration
Confirming cytotoxic CD8+ T-cell infiltration and durable tumour regression in vivo.
Early Clinical Design
Structuring phase I basket trial protocols guided by predictive molecular biomarker signatures.
Connect with our translational research team at contact@triplehelixscience.com